Investing.com - Cogent Biosciences reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was inline with expectations.
Cogent Biosciences announced earnings per share of $-0.500 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.513 on revenue of $0.00.
Cogent Biosciences shares are down 45% from the beginning of the year and are trading at $12.130 , down-from-52-week-high.
Cogent Biosciences shares lost 2.33% in intra-day trade after the report.
Cogent Biosciences follows other major Healthcare sector earnings this month
Cogent Biosciences's report follows an earnings beat by J&J on Tuesday, October 18, 2022, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on Tuesday, November 1, 2022 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar